216 related articles for article (PubMed ID: 34759925)
21. HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities.
Santin AD; Bellone S; Palmieri M; Ravaggi A; Romani C; Tassi R; Roman JJ; Burnett A; Pecorelli S; Cannon MJ
Gynecol Oncol; 2006 Mar; 100(3):469-78. PubMed ID: 16249018
[TBL] [Abstract][Full Text] [Related]
22. Human papillomavirus 16-specific T-cell responses and spontaneous regression of anal high-grade squamous intraepithelial lesions.
Tong WW; Shepherd K; Garland S; Meagher A; Templeton DJ; Fairley CK; Jin F; Poynten IM; Zaunders J; Hillman RJ; Grulich AE; Kelleher AD; Carr A;
J Infect Dis; 2015 Feb; 211(3):405-15. PubMed ID: 25139018
[TBL] [Abstract][Full Text] [Related]
23. HPV16-specific cytotoxic T lymphocyte responses are detected in all HPV16-positive cervical cancer patients.
Valdespino V; Gorodezky C; Ortiz V; Kaufmann AM; Roman-Basaure E; Vazquez A; Berumen J
Gynecol Oncol; 2005 Jan; 96(1):92-102. PubMed ID: 15589586
[TBL] [Abstract][Full Text] [Related]
24. Induction of human papillomavirus type 16-specific immunologic responses in a normal and an human papillomavirus-infected populations.
Cheng WF; Lee CN; Su YN; Chang MC; Hsiao WC; Chen CA; Hsieh CY
Immunology; 2005 May; 115(1):136-49. PubMed ID: 15819706
[TBL] [Abstract][Full Text] [Related]
25. Comparison of cervical and blood T-cell responses to human papillomavirus-16 in women with human papillomavirus-associated cervical intraepithelial neoplasia.
Passmore JA; Milner M; Denny L; Sampson C; Marais DJ; Allan B; Gumbi PP; Hitzeroth II; Rybicki EP; Williamson AL
Immunology; 2006 Dec; 119(4):507-14. PubMed ID: 17026720
[TBL] [Abstract][Full Text] [Related]
26. Cell mediated immunity against HPV16 E2, E6 and E7 peptides in women with incident CIN and in constantly HPV-negative women followed-up for 10-years.
Paaso A; Koskimaa HM; Welters MJ; Grénman S; Syrjänen K; van der Burg SH; Syrjänen S
J Transl Med; 2015 May; 13():163. PubMed ID: 25990808
[TBL] [Abstract][Full Text] [Related]
27. Surgery followed by persistence of high-grade squamous intraepithelial lesions is associated with the induction of a dysfunctional HPV16-specific T-cell response.
de Vos van Steenwijk PJ; Piersma SJ; Welters MJ; van der Hulst JM; Fleuren G; Hellebrekers BW; Kenter GG; van der Burg SH
Clin Cancer Res; 2008 Nov; 14(22):7188-95. PubMed ID: 19010835
[TBL] [Abstract][Full Text] [Related]
28. Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination.
Smyth LJ; Van Poelgeest MI; Davidson EJ; Kwappenberg KM; Burt D; Sehr P; Pawlita M; Man S; Hickling JK; Fiander AN; Tristram A; Kitchener HC; Offringa R; Stern PL; Van Der Burg SH
Clin Cancer Res; 2004 May; 10(9):2954-61. PubMed ID: 15131030
[TBL] [Abstract][Full Text] [Related]
29. Type-dependent E6/E7 mRNA expression of single and multiple high-risk human papillomavirus infections in cervical neoplasia.
Andersson E; Kärrberg C; Rådberg T; Blomqvist L; Zetterqvist BM; Ryd W; Lindh M; Horal P
J Clin Virol; 2012 May; 54(1):61-5. PubMed ID: 22326759
[TBL] [Abstract][Full Text] [Related]
30. TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16.
Hasan UA; Bates E; Takeshita F; Biliato A; Accardi R; Bouvard V; Mansour M; Vincent I; Gissmann L; Iftner T; Sideri M; Stubenrauch F; Tommasino M
J Immunol; 2007 Mar; 178(5):3186-97. PubMed ID: 17312167
[TBL] [Abstract][Full Text] [Related]
31. Antibodies against high-risk human papillomavirus proteins as markers for invasive cervical cancer.
Combes JD; Pawlita M; Waterboer T; Hammouda D; Rajkumar T; Vanhems P; Snijders P; Herrero R; Franceschi S; Clifford G
Int J Cancer; 2014 Nov; 135(10):2453-61. PubMed ID: 24729277
[TBL] [Abstract][Full Text] [Related]
32. Cell-mediated immune responses to human papillomavirus 16 E6 and E7 antigens as measured by interferon gamma enzyme-linked immunospot in women with cleared or persistent human papillomavirus infection.
Farhat S; Nakagawa M; Moscicki AB
Int J Gynecol Cancer; 2009 May; 19(4):508-12. PubMed ID: 19509544
[TBL] [Abstract][Full Text] [Related]
33. Human papilloma virus early proteins E6 (HPV16/18-E6) and the cell cycle marker P16 (INK4a) are useful prognostic markers in uterine cervical carcinomas in Qassim Region--Saudi Arabia.
Omran OM; AlSheeha M
Pathol Oncol Res; 2015 Jan; 21(1):157-66. PubMed ID: 24925218
[TBL] [Abstract][Full Text] [Related]
34. Elevated Expression of Human Papillomavirus-16/18 E6 Oncoprotein Associates with Persistence of Viral Infection: A 3-Year Prospective Study in China.
Yu LL; Kang LN; Zhao FH; Lei XQ; Qin Y; Wu ZN; Wang H; Chen W; Qiao YL
Cancer Epidemiol Biomarkers Prev; 2016 Jul; 25(7):1167-74. PubMed ID: 27197295
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of HPV 16 and HPV 18 Oncoprotein Expression as Alternative Diagnostic Tools in Cervical Lesion.
Sabri NA; Shamsuddin SH; Mat Zin AA
Asian Pac J Cancer Prev; 2024 Feb; 25(2):521-527. PubMed ID: 38415538
[TBL] [Abstract][Full Text] [Related]
36. Distinct regulation and impact of type 1 T-cell immunity against HPV16 L1, E2 and E6 antigens during HPV16-induced cervical infection and neoplasia.
van Poelgeest MI; Nijhuis ER; Kwappenberg KM; Hamming IE; Wouter Drijfhout J; Fleuren GJ; van der Zee AG; Melief CJ; Kenter GG; Nijman HW; Offringa R; van der Burg SH
Int J Cancer; 2006 Feb; 118(3):675-83. PubMed ID: 16108057
[TBL] [Abstract][Full Text] [Related]
37. E6/E7 and E6
Artaza-Irigaray C; Molina-Pineda A; Aguilar-Lemarroy A; Ortiz-Lazareno P; Limón-Toledo LP; Pereira-Suárez AL; Rojo-Contreras W; Jave-Suárez LF
Front Immunol; 2019; 10():1676. PubMed ID: 31396215
[TBL] [Abstract][Full Text] [Related]
38. Vaccination of full-length HPV16 E6 or E7 protein inhibits the growth of HPV16 associated tumors.
Li YL; Qiu XH; Shen C; Liu JN; Zhang J
Oncol Rep; 2010 Nov; 24(5):1323-9. PubMed ID: 20878127
[TBL] [Abstract][Full Text] [Related]
39. Human papillomavirus type 16 E7 peptide-directed CD8+ T cells from patients with cervical cancer are cross-reactive with the coronavirus NS2 protein.
Nilges K; Höhn H; Pilch H; Neukirch C; Freitag K; Talbot PJ; Maeurer MJ
J Virol; 2003 May; 77(9):5464-74. PubMed ID: 12692247
[TBL] [Abstract][Full Text] [Related]
40. Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes for adoptive immunotherapy of HPV-associated malignancies.
Ramos CA; Narala N; Vyas GM; Leen AM; Gerdemann U; Sturgis EM; Anderson ML; Savoldo B; Heslop HE; Brenner MK; Rooney CM
J Immunother; 2013 Jan; 36(1):66-76. PubMed ID: 23211628
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
